Published in Mol Cell Biol on February 12, 2007
Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol (2014) 10.04
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res (2010) 3.53
Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med (2009) 3.05
Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Metastasis (2008) 2.86
Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal (2014) 2.42
Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis (2007) 2.41
Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis (2008) 2.30
TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer (2010) 2.30
The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha. Mol Endocrinol (2007) 1.95
A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastasis (2010) 1.95
FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res (2013) 1.76
miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology (2010) 1.66
NF-κB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res (2010) 1.58
Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression. Cell Tissue Res (2011) 1.53
Retracted Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res (2010) 1.51
Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev (2008) 1.38
miR-506 regulates epithelial mesenchymal transition in breast cancer cell lines. PLoS One (2013) 1.31
EMT and tumor metastasis. Clin Transl Med (2015) 1.29
Snail1 is stabilized by O-GlcNAc modification in hyperglycaemic condition. EMBO J (2010) 1.23
Sustained c-Jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation. Mol Cancer Res (2010) 1.21
Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J Biol Chem (2011) 1.21
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res (2010) 1.20
The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol (2010) 1.13
Regulation of NF-κB by the CARD proteins. Immunol Rev (2012) 1.12
CARMA3 is crucial for EGFR-Induced activation of NF-κB and tumor progression. Cancer Res (2011) 1.10
Targeting insulin and insulin-like growth factor signaling in breast cancer. J Mammary Gland Biol Neoplasia (2012) 1.08
IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Sci Rep (2013) 1.07
Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance. Curr Pharm Des (2015) 1.01
14-3-3 binding sites in the snail protein are essential for snail-mediated transcriptional repression and epithelial-mesenchymal differentiation. Cancer Res (2010) 1.01
A comparison of epithelial-to-mesenchymal transition and re-epithelialization. Semin Cancer Biol (2012) 1.00
The insulin receptor: a new target for cancer therapy. Front Endocrinol (Lausanne) (2011) 0.99
Systems biology approaches to understanding Epithelial Mesenchymal Transition (EMT) in mucosal remodeling and signaling in asthma. World Allergy Organ J (2014) 0.97
BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells. Clin Cancer Res (2009) 0.97
The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. Cell Death Dis (2013) 0.95
Beta1 integrins mediate cell proliferation in three-dimensional cultures by regulating expression of the sonic hedgehog effector protein, GLI1. J Cell Physiol (2010) 0.93
RhoGDI2 promotes epithelial-mesenchymal transition via induction of Snail in gastric cancer cells. Oncotarget (2014) 0.93
Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Crit Rev Oncog (2012) 0.92
Systems approaches to modeling chronic mucosal inflammation. Biomed Res Int (2013) 0.91
Ubiquitin ligase Cbl-b represses IGF-I-induced epithelial mesenchymal transition via ZEB2 and microRNA-200c regulation in gastric cancer cells. Mol Cancer (2014) 0.90
Growth factors in tumor microenvironment. Front Biosci (Landmark Ed) (2010) 0.88
Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. Am J Transl Res (2009) 0.87
Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-β treatment. Am J Pathol (2011) 0.87
Mesenchymal Stromal Cells Epithelial Transition Induced by Renal Tubular Cells-Derived Extracellular Vesicles. PLoS One (2016) 0.86
Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer. Br J Cancer (2010) 0.86
Inactivation of RARβ inhibits Wnt1-induced mammary tumorigenesis by suppressing epithelial-mesenchymal transitions. Nucl Recept Signal (2014) 0.86
Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells. J Biol Chem (2010) 0.86
Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605. BMC Cancer (2009) 0.86
Analysis of the TGFβ-induced program in primary airway epithelial cells shows essential role of NF-κB/RelA signaling network in type II epithelial mesenchymal transition. BMC Genomics (2015) 0.86
Parity-induced decrease in systemic growth hormone alters mammary gland signaling: a potential role in pregnancy protection from breast cancer. Cancer Prev Res (Phila) (2010) 0.85
Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor-binding protein 3? Breast Cancer (Dove Med Press) (2015) 0.85
Inflammation and tumor microenvironment in lymph node metastasis. Cancers (Basel) (2011) 0.85
The human IGF1R IRES likely operates through a Shine-Dalgarno-like interaction with the G961 loop (E-site) of the 18S rRNA and is kinetically modulated by a naturally polymorphic polyU loop. J Cell Biochem (2010) 0.85
Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation. Front Endocrinol (Lausanne) (2015) 0.85
The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Transl Lung Cancer Res (2016) 0.85
Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer. Oncotarget (2015) 0.85
The double-edged sword: conserved functions of extracellular hsp90 in wound healing and cancer. Cancers (Basel) (2014) 0.82
Insulin-like growth factors are more effective than progastrin in reversing proapoptotic effects of curcumin: critical role of p38MAPK. Am J Physiol Gastrointest Liver Physiol (2010) 0.82
The NF-κB Pathway and Cancer Stem Cells. Cells (2016) 0.82
Type 1 Insulin-Like Growth Factor Receptor/Insulin Receptor Substrate 1 Signaling Confers Pathogenic Activity on Breast Tumor Cells Lacking REST. Mol Cell Biol (2015) 0.80
BI 5700, a Selective Chemical Inhibitor of IκB Kinase 2, Specifically Suppresses Epithelial-Mesenchymal Transition and Metastasis in Mouse Models of Tumor Progression. Genes Cancer (2010) 0.80
The motile breast cancer phenotype roles of proteoglycans/glycosaminoglycans. Biomed Res Int (2014) 0.80
On how CCN6 suppresses breast cancer growth and invasion. J Cell Commun Signal (2011) 0.80
Epithelial-mesenchymal transition in tissue repair and fibrosis. Cell Tissue Res (2016) 0.79
Northwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological activation of the IGF1R IRES. Exp Mol Pathol (2010) 0.79
Insulin-like growth factor-I induces epithelial to mesenchymal transition via GSK-3β and ZEB2 in the BGC-823 gastric cancer cell line. Oncol Lett (2014) 0.79
Essential function for PDLIM2 in cell polarization in three-dimensional cultures by feedback regulation of the β1-integrin-RhoA signaling axis. Neoplasia (2014) 0.78
Radiation induces the generation of cancer stem cells: A novel mechanism for cancer radioresistance. Oncol Lett (2016) 0.78
Proteomic Screening and Lasso Regression Reveal Differential Signaling in Insulin and Insulin-like Growth Factor I (IGF1) Pathways. Mol Cell Proteomics (2016) 0.78
IGF-1 Receptor and Adhesion Signaling: An Important Axis in Determining Cancer Cell Phenotype and Therapy Resistance. Front Endocrinol (Lausanne) (2015) 0.77
IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights. Mol Cancer (2017) 0.76
BRD4 mediates NF-κB-dependent epithelial-mesenchymal transition and pulmonary fibrosis via transcriptional elongation. Am J Physiol Lung Cell Mol Physiol (2016) 0.76
EMT reversal in human cancer cells after IR knockdown in hyperinsulinemic mice. Endocr Relat Cancer (2016) 0.75
Medaka insulin-like growth factor-2 supports self-renewal of the embryonic stem cell line and blastomeres in vitro. Sci Rep (2017) 0.75
cPLA2α mediates TGF-β-induced epithelial-mesenchymal transition in breast cancer through PI3k/Akt signaling. Cell Death Dis (2017) 0.75
Snail modulated miR - 493 forms a negative feedback loop with IGF1R pathway and blocks tumorigenesis. Mol Cell Biol (2016) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell (2004) 31.38
Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods (2003) 18.51
Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol (2005) 11.46
Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol (2003) 11.12
TGF-beta and epithelial-to-mesenchymal transitions. Oncogene (2005) 10.02
Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol (2004) 9.80
An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) (1995) 9.18
Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer (2005) 8.70
The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development (2005) 8.42
The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell (2005) 5.81
NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest (2004) 5.06
Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol (2005) 5.00
Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem (2000) 5.00
Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol (2003) 4.53
Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol (2002) 3.82
The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res (2003) 3.58
A requirement for CARMA1 in TCR-induced NF-kappa B activation. Nat Immunol (2002) 3.38
Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol (2000) 3.34
EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res (2001) 3.24
Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int (2002) 3.16
Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene (2000) 3.08
NF-kappaB as a therapeutic target in cancer. Trends Mol Med (2002) 3.08
Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol (2005) 2.88
AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest (2006) 2.74
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene (2002) 2.66
Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells. Oncogene (2004) 2.44
Unraveling signalling cascades for the Snail family of transcription factors. Cell Signal (2005) 2.17
The expression levels of the transcriptional regulators p300 and CtBP modulate the correlations between SNAIL, ZEB1, E-cadherin and vitamin D receptor in human colon carcinomas. Int J Cancer (2006) 1.91
Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol (1990) 1.90
Transcriptional repressor snail and progression of human hepatocellular carcinoma. Clin Cancer Res (2003) 1.79
Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia (2000) 1.73
Transforming growth factor-beta and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent mechanism in primary cultured pig thyrocytes. J Cell Sci (2002) 1.72
The IGF-I receptor in cancer research. Exp Cell Res (1999) 1.64
Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res (2005) 1.58
Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol (2006) 1.58
Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol (2004) 1.55
Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology (2001) 1.46
Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene (2006) 1.44
Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary cells. Carcinogenesis (2000) 1.38
Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes. Int J Cancer (1995) 1.27
Mammary epithelial cell transformation: insights from cell culture and mouse models. Breast Cancer Res (2005) 1.26
Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J Med Chem (2005) 1.22
Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia (2006) 1.22
Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer Res (2005) 1.14
Type I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells. Breast Cancer Res (2006) 1.14
The activated insulin-like growth factor I receptor induces depolarization in breast epithelial cells characterized by actin filament disassembly and tyrosine dephosphorylation of FAK, Cas, and paxillin. Exp Cell Res (1999) 1.04
Lipoxin A4 modifies platelet-derived growth factor-induced pro-fibrotic gene expression in human renal mesangial cells. Am J Pathol (2005) 0.92
IGF-1: old growth factor shines as new drug target. J Natl Cancer Inst (2005) 0.90
Effects of herbal compound 861 on human hepatic stellate cell proliferation and activation. World J Gastroenterol (2004) 0.89
The role of the insulin-like growth factor I receptor in transformation and apoptosis. Ann N Y Acad Sci (1998) 0.87
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science (2009) 4.63
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst (2005) 4.25
A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res (2008) 4.06
A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science (2013) 3.96
The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. Nat Immunol (2006) 3.76
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol (2008) 3.74
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol (2005) 3.62
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res (2010) 3.53
A requirement for CARMA1 in TCR-induced NF-kappa B activation. Nat Immunol (2002) 3.38
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 3.36
Phosphorylation of CARMA1 plays a critical role in T Cell receptor-mediated NF-kappaB activation. Immunity (2005) 3.14
Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development (2007) 3.07
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res (2007) 2.84
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res (2013) 2.63
Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle (2007) 2.48
Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappaB activation. J Biol Chem (2006) 2.32
Differential use of CARD9 by dectin-1 in macrophages and dendritic cells. J Immunol (2009) 2.23
Evaluation of terrestrial carbon cycle models for their response to climate variability and to CO2 trends. Glob Chang Biol (2013) 2.13
Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res (2010) 2.13
Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med (2014) 2.09
AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res (2004) 2.07
The effect of combined antihypertensive treatment (felodipine with either irbesartan or metoprolol) on erectile function: a randomized controlled trial. Cardiology (2013) 2.02
CD3/CD28 costimulation-induced NF-kappaB activation is mediated by recruitment of protein kinase C-theta, Bcl10, and IkappaB kinase beta to the immunological synapse through CARMA1. Mol Cell Biol (2004) 1.96
Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells--implications for pregnancy-induced protection against breast cancer. Stem Cells (2008) 1.96
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci (2008) 1.88
The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res (2009) 1.78
Crucial role for nuclear factor of activated T cells in T cell receptor-mediated regulation of human interleukin-17. J Biol Chem (2004) 1.77
Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy. Mol Cancer Res (2011) 1.76
FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res (2010) 1.73
Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res (2009) 1.72
Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res (2009) 1.71
Interaction between P-TEFb and the C-terminal domain of RNA polymerase II activates transcriptional elongation from sites upstream or downstream of target genes. Mol Cell Biol (2002) 1.68
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Proinflammatory protein CARD9 is essential for infiltration of monocytic fibroblast precursors and cardiac fibrosis caused by Angiotensin II infusion. Am J Hypertens (2011) 1.67
Pygo2 expands mammary progenitor cells by facilitating histone H3 K4 methylation. J Cell Biol (2009) 1.65
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther (2009) 1.62
Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models. Proc Natl Acad Sci U S A (2006) 1.60
NF-κB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res (2010) 1.58
Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol (2005) 1.58
Evidence of recombination and genetic diversity in human rhinoviruses in children with acute respiratory infection. PLoS One (2009) 1.58
Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res (2005) 1.58
Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol (2006) 1.58
Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate (2010) 1.54
Genome-wide search for type 2 diabetes/impaired glucose homeostasis susceptibility genes in the Chinese: significant linkage to chromosome 6q21-q23 and chromosome 1q21-q24. Diabetes (2004) 1.54
Phosphorylation and ubiquitination of the IkappaB kinase complex by two distinct signaling pathways. EMBO J (2007) 1.54
Retracted Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res (2010) 1.51
Positive and negative signaling components involved in TNFalpha-induced NF-kappaB activation. Cytokine (2008) 1.50
Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One (2010) 1.49
Biosynthesis of the sesquiterpene antibiotic albaflavenone in Streptomyces coelicolor A3(2). J Biol Chem (2008) 1.48
TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood (2012) 1.47
Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension. J Hypertens (2012) 1.47
C-type lectin receptors Dectin-3 and Dectin-2 form a heterodimeric pattern-recognition receptor for host defense against fungal infection. Immunity (2013) 1.46
Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci U S A (2006) 1.46
A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res (2013) 1.46
Tracing conidial fate and measuring host cell antifungal activity using a reporter of microbial viability in the lung. Cell Rep (2012) 1.45
CARMA3 deficiency abrogates G protein-coupled receptor-induced NF-{kappa}B activation. Genes Dev (2007) 1.45
CARMA1-mediated NF-kappaB and JNK activation in lymphocytes. Immunol Rev (2009) 1.44
Bcl10 plays a critical role in NF-kappaB activation induced by G protein-coupled receptors. Proc Natl Acad Sci U S A (2006) 1.44
p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop. EMBO J (2003) 1.44
Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res (2015) 1.43
The CARMA1-Bcl10 signaling complex selectively regulates JNK2 kinase in the T cell receptor-signaling pathway. Immunity (2006) 1.40
HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther (2008) 1.40
Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev (2008) 1.38
A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem (2003) 1.38
Declining snow cover may affect spring phenological trend on the Tibetan Plateau. Proc Natl Acad Sci U S A (2013) 1.38
MALT1/paracaspase is a signaling component downstream of CARMA1 and mediates T cell receptor-induced NF-kappaB activation. J Biol Chem (2004) 1.38
Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res (2009) 1.37
Disruption of steroid and prolactin receptor patterning in the mammary gland correlates with a block in lobuloalveolar development. Mol Endocrinol (2002) 1.37
Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. Cancer Res (2006) 1.37
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat (2009) 1.35
Early airway pressure release ventilation prevents ARDS-a novel preventive approach to lung injury. Shock (2013) 1.35
Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat (2008) 1.34
In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res (2006) 1.34
The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. Immunity (2010) 1.31
Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol Cancer Ther (2008) 1.31
TAK1 is recruited to the tumor necrosis factor-alpha (TNF-alpha) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3 leading to NF-kappaB activation. J Biol Chem (2005) 1.28
The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol (2011) 1.27
Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo). Breast Cancer Res Treat (2008) 1.27